Clinical Trial Details
— Status: Completed
Administrative data
| NCT number |
NCT03600194 |
| Other study ID # |
AI-16052-PSCOMP-LO |
| Secondary ID |
|
| Status |
Completed |
| Phase |
N/A
|
| First received |
|
| Last updated |
|
| Start date |
June 1, 2018 |
| Est. completion date |
July 25, 2019 |
Study information
| Verified date |
May 2021 |
| Source |
Philips Respironics |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Interventional
|
Clinical Trial Summary
This study is a randomized, single-blind, sham-controlled pilot cross-over trial comparing
the feasibility, and efficacy of 2 nights of in lab use with active versus sham conditions in
adults with sleep restricted schedules. The study involves the testing of 2 different
prototypes both in the sham and active conditions The expected duration of the study for each
participant is up to 5 weeks. It will include adults (21-50 yr. old) who report shortened
sleep due to lifestyle. For the purposes of this study, shortened sleep is defined as
sleeping at least 5.5 of sleep per night, and sleeping less than or equal to 7 hours of sleep
+/- 15 minutes on at least 3/5 work/school nights. Participants also increase their sleep
duration by ≥ 1 hour on non-work/school days. In addition, participants report a sleep
latency ≤ 30 minutes and wake after sleep onset ≤ 30 minutes. Participants are generally
healthy individuals who have not been diagnosed with any sleep-related medical conditions
such as obstructive sleep apnea, insomnia, difficulty falling asleep on a nightly basis and
deny difficulty staying asleep if awoken during sleep. In addition, participants diagnosed
with major organ system diseases or requiring oxygen therapy are excluded from participation.
Up to 60 individuals will be consented in order to complete a total of 10 participants using
a cross over design. The study involves an initial screening visit followed by 1 week of
actigraphy measurement to determine eligibility. Post eligibility, participants will undergo
an additional week of actigraphy measurement. Participants will complete 2 overnight visits
in the sleep lab per week, with one washout night in between. They will be randomly assigned
to sham or active condition during the first of the overnight visits, and the other condition
during the second overnight condition. Participants will return to the lab on the same nights
the next week and receive the second device in both conditions. Participants will be asked to
complete a battery of cognitive tests upon wake up in the lab after each of the overnight
visits.
Description:
Each subject will undergo a baseline screening period with screening questionnaires, clinical
history, and 1 week of actigraphy measurement to determine eligibility for inclusion in the
study. Prior to the overnight study they will undergo an additional 1 week of actigraphy
measurement. Each subject will have two 3 day/2 night stays, separated by one week. Including
outpatient screening and the inpatient study periods, the duration of participation for each
subject will be ~5 weeks. We anticipate 6 months to enroll and complete the 12 subjects.
Primary data analysis should be completed within one year of starting this study.
Study Procedures:
Participants may be screened over the phone to determine eligibility. A screening script will
include a general review of key inclusion and exclusion criteria, and the Stop-Bang
Questionnaire to assess risk for undiagnosed obstructive sleep apnea. Participants that meet
all eligibility criteria will be asked to come into the research lab for a brief daytime
screening visit. Participants who are interested and eligible will be consented. Participants
will be provided with information on use of the actigraph and sleep logs at home.
Participants will be asked to return their actigraph and sleep logs to the laboratory either
in person or via pre-paid FedEx. Participant qualification will be assessed based on sleep
logs and the actigraph results. Qualifying participants will wear the actigraph and fill out
sleep logs again for the week prior to their first overnight visit.
Visit 1 (Screening) Procedures (up to 2 hours):
Participants will be asked to report to the research office for a daytime visit. A detailed
interview will be performed verifying eligibility criteria, as well as a review of work and
non-work schedules. After a full explanation of the protocol and after all the participants
questions have been answered, they will be asked to sign the consent form. Written
documentation of consent will be obtained for all subjects.
Participants will complete the following baseline questions:
Demographics Medical History Questionnaire Collection of Current Medications Epworth
Sleepiness Scale (ESS) Insomnia Severity Index Questionnaire (ISI) (if not completed during
telephone screen) Stop-Bang (if not completed during telephone screen) Cambridge Hopkins
(Restless Leg Syndrome) Questionnaire (if not completed during phone screen)
Participants will have their height, weight, neck circumference, temperature, heart rate and
blood pressure recorded. Women of child bearing potential will have a urine pregnancy test.
Participants will be trained in the use of the sleep logs and actigraphy.
Actigraphy screening:
Participants will be asked to wear an actigraph and complete a daily sleep diary for 7 days
+2 days to monitor their sleep schedule. Participants will receive instructions from the
study staff on how to wear the actigraph and will be asked to keep to their regular sleep
schedule.
Assessment training:
Participants will also be trained on daytime assessments which will be completed during the
overnight visits. Only participants that are able to perform the task will be asked to remain
in the study and through completion.
Actigraphy review:
Participants will drop off or mail their actigraph and sleep log to the research office for
review by the study staff. The actigraph data will be reviewed by a trained technologist.
Only participants that demonstrate a regular sleep schedule and an average sleep duration of
6-7 hours during the work week will be asked to return to the lab for the study. A regular
sleep schedule will be defined as a bedtime between 9pm and midnight with no more than 1 hour
of variability across the 7 nights. Qualifying participants will be asked to continue wearing
the actiwatch and completing the sleep diary throughout the remainder of the study.
Visit 2 Procedures (3 days/2 nights with washout in between nights):
Participants will be randomly assigned to the sham or active stimulation condition during the
first night of the overnight visits, and the other condition (sham or active stimulation)
during the second night of the overnight visits. Participants may also be asked to undergo
additional night study testing if data collected is unable to be analyzed due to unforeseen
technical or environmental reasons. Participants and study staff will be blinded to the
condition they are receiving during each overnight study for prototype 1. However, study
staff will not be blinded during each overnight for prototype 2.
Active condition: Participants will be set-up with one of the PowerSleep Prototypes. Soft
audio tones (below 65dB to prevent arousals from sleep) will be administered via the
headphones during deep sleep throughout the night.
Sham condition: Participants will be set up with the same PowerSleep prototype as with the
active arm, however no audio tones will be played.
Participants will typically be asked to arrive at the Sleep Lab ~3 hours before their usual
bedtime.
Upon arriving at the sleep lab for the first overnight study, the actigraph data will be
downloaded for review by a trained technologist. Only participants that demonstrate a regular
sleep schedule and a sleep duration of 6-7 hours per night will be asked to remain in the
study and through completion.
The Paired Associated Learning (PAL) learning set will be completed before the participant
goes to bed.
Overnight monitoring:
Participants will complete an attended overnight polysomnogram (PSG). During all PSGs, the
electroencephalogram (EEG), electrooculogram (EOG) and sub-mental electromyogram (EMG) will
be recorded with surface electrodes according to American Academy of Sleep Medicine (AASM)
standards. In addition, surface ECG electrodes (standard lead II) will be applied to the
participant. All PSG signals will be recorded and monitored continuously by a trained sleep
technologist throughout the night.
After the baseline recordings while awake, the PSG channels indicated above will be recorded
for the participants' entire night of sleep. Participants will be in a private room with the
door closed and lights off. During the overnight recordings, participants will be directly
observed via video camera. The participant can contact the trained technologist present at
any time via an intercom.
During overnight studies under the active condition, soft auditory tones will be provided via
the speakers during N3 sleep for prototype 1 and N2 or N3 sleep for prototype 2.
Morning:
The participant will be awakened at their usual wake time according to sleep logs and
actigraphy
Participants will be asked to complete daytime assessments each morning of the visit (90
minutes post awakening) including:
Karolinska Sleepiness Scale (KSS) Samn & Perelli Fatigue Scale Visual Analog Scale (VAS)
sleep quality Matrix Reasoning Task (MRT) (to be completed on iPad) Digit Symbol Substitution
Task (DSST) (to be completed on iPad) Psychomotor Vigilance Test (PVT-B - 3min) (to be
completed on iPad) Paired Associates Learning (PAL)
The DSST, MRT, PVT-B and PAL assessments will be completed electronically and the other
assessments will be completed in paper form.
The actigraph data will be downloaded and the re-configured actigraphy device will be
returned to the participant to be worn for the period before Visit 4. Sleep logs will be
given for the participant to fill out during any time at home.
The subject will be allowed to go home or to work during the day and will be instructed not
to nap during the day. This will be monitored with the actigraph. The subject will return to
the lab the following evening 3 hours before the usual bedtime and will be instrumented and
studied as described for night 1. For example, participants that spent the night Monday and
completed Tuesday morning testing will come into the lab Wednesday night for Thursday morning
testing or if participants sent Tuesday night and completed Wednesday morning testing they
will come into the lab Thursday night for Friday morning testing.
Visit 4 Procedures (3 days/2 nights):
Participants will return to the Sleep Disorders Center to complete the second set of
overnight studies one or two weeks after the first set of overnight studies. If participants
spent Monday and Wednesday night in the lab for the first set of overnight studies, they will
complete the second set of overnight visits Monday and Wednesday. The actigraph data will be
similarly downloaded and reviewed for further participation upon arriving at the Sleep
Disorders Center. This visit will be identical to Visit 3 except that the subjects will
receive the prototype system that was not used in Visit 3 (Prototype 1 or 2).
